HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Valvular Heart Disease

 

ACC and AHA Release Updated Guidance for Diagnosis and Management of Aortic Disease

November 03, 2022

Released on Nov. 2, the 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease were created to be used concurrently with guidance published in 2020 and to replace previous guidance published in 2010 and 2015.

Cardiology Month in Review: September 2022

September 24, 2022

The final weekend of each month, our editorial staff compiles a list of our most popular content from the past month. The top content from September 2022 includes trio of FDA approvals, a TCT headliner, a look back at ESC Congress 22, and a new prognostic biomarker for heart failure.

PASCAL System Demonstrates Noninferiority to MitraClip for DMR in CLASP IID Trial

September 19, 2022

Data from the CLASP IID trial provide insight into the benefits of the PASCAL TEER system for degenerative mitral regurgitation, which demonstrated noninferiority to the MitraClip system for the trial's primary safety and efficacy endpoints.

PROTECTED TAVR: Cerebral Embolic Protection Devices Do Not Reduce Stroke Risk

September 17, 2022

Results of the PROTECTED TAVR trial suggest use of cerebral embolic protection devices was not associated with a reduction in risk of stroke within the first 72 hours after TAVR or prior to hospital discharge among patients with aortic stenosis.

FDA Approves PASCAL Precision System for TEER in Degenerative Mitral Regurgitation

September 16, 2022

Announced on September 15 by Edwards Lifesciences Corporation, the PASCAL Precision transcatheter valve repair system has received approval for transcatheter edge-to-edge repair in patients with degenerative mitral regurgitation.

Cardiology Month in Review: July 2022

July 30, 2022

Our cardiology month in review spotlights the most popular content from the past month. The top content from July 2022 includes hormone therapy guidance from NAMS, a look at the potential for increased risk of kidney damage with a popular statin, and a recap of upcoming decisions and trials of interest in cardiometabolic from the second half of 2022.